HKSE:0874

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited · HKSE · Healthcare · HKD · FY for 2024

Figures on this page computed 2026-11-08 13:34 UTC

Last close

n/aHKD

Market data

6.4xP/E
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-08
Reported in
HKD
- computed
- Computed from the filing for 2024
10.0%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2024
- Computed from the filing for 2024
- Computed from the filing for 2024
- Computed from the filing for 2024
- Computed from the filing for 2024
- Computed from the filing for 2024
3.8%Net margin
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2024
- Computed from the filing for 2024
3.1%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2024
- Computed from the filing for 2024
0.34Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2024
- Computed from the filing for 2024
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-08
Reported in
HKD
- computed

What it pays out is the furthest below its sector's middle: 0.21 against 0.54 on the market's range.

All from 100

lens 2 of 9

Sales

392

2015-12-31 to 2024-12-31100 at the start392

Sales: 100.00 on 2015-12-31 to 392.13 on 2024-12-31, up 292%.

Profit

218

2015-12-31 to 2024-12-31100 at the start218

Profit: 100.00 on 2015-12-31 to 218.06 on 2024-12-31, up 118%.

Shares in issue

126

2015-12-31 to 2024-12-31100 at the start126

Shares in issue: 100.00 on 2015-12-31 to 125.91 on 2024-12-31, up 26%.

Sales is at 392, Profit is at 218, Shares in issue is at 126, against 100 in 2015.

Sales is at 392, Profit is at 218, Shares in issue is at 126, against 100 in 2015.

Every figure in this lens

Except where said otherwise: Computed from the filing for 2024

Sales, where the first year is 100392
Source
computed
Statement
income
Fiscal year
2024
Reported in
CNY
Profit, where the first year is 100218
Source
computed
Statement
income
Fiscal year
2024
Reported in
CNY
Shares in issue, where the first year is 100126
Source
computed
Statement
income
Fiscal year
2024
Reported in
CNY